Rhynchophylline prevents cardiac dysfunction and improves survival in lipopolysaccharide-challenged mice via suppressing macrophage I-κBα phosphorylation
Myocardial dysfunction is a common complication during sepsis and significantly contributes to the mortality of patients with septic shock. However, none of the available therapeutic strategies proven to be effective in patients with severe sepsis are designed specifically to target myocardial dysfu...
Gespeichert in:
Veröffentlicht in: | International immunopharmacology 2012-11, Vol.14 (3), p.243-251 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 251 |
---|---|
container_issue | 3 |
container_start_page | 243 |
container_title | International immunopharmacology |
container_volume | 14 |
creator | Cao, Wenjuan Wang, Yuan Lv, Xiuxiu Yu, Xiaohui Li, Xiaojian Li, Hongmei Wang, Yanping Lu, Daxiang Qi, Renbin Wang, Huadong |
description | Myocardial dysfunction is a common complication during sepsis and significantly contributes to the mortality of patients with septic shock. However, none of the available therapeutic strategies proven to be effective in patients with severe sepsis are designed specifically to target myocardial dysfunction. The purpose of the present study is to investigate the effect of rhynchophylline (Rhy) on LPS-induced myocardial dysfunction in mice. We found that pretreatment with Rhy significantly improved cardiac systolic dysfunction, increased stroke volume and cardiac output in mice challenged with LPS. LPS induced cardiac inhibitor-κBα (I-κBα) phosphorylation, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) mRNA expression, and in turn increased cardiac TNF-α and IL-1β protein production, all of which were attenuated by pretreatment with Rhy. Immunohistochemistry revealed that TNF-α was found in infiltrated macrophages (F4/80+) and myocardium, and Rhy reduced TNF-α immunostaining in cardiac infiltrated macrophages in LPS-challenged mice. Furthermore, Rhy inhibited LPS-induced I-κBα phosphorylation and TNF-α production in cultured mouse peritoneal macrophages, but not in neonatal mouse cardiomyocytes. Pretreatment with Rhy significantly decreased the mortality of LPS-challenged mice. These results indicate that Rhy reduces cardiac dysfunction and improves survival via suppression of macrophage I-κBα phosphorylation in LPS-challenged mice, and suggest that Rhy may be a potential agent for the treatment of septic cardiac dysfunction.
[Display omitted]
► Rhynchophylline inhibited LPS-induced I-κBα phosphorylation in macrophages. ► Rhynchophylline did not block LPS-induced TNF-α production in cardiomyocytes. ► Rhynchophylline inhibited LPS-induced cardiac I-κBα phosphorylation. ► Rhynchophylline inhibited LPS-induced cardiac TNF-α and IL-1β expression. ► Rhynchophylline improved cardiac dysfunction and survival in LPS-challenged mice. |
doi_str_mv | 10.1016/j.intimp.2012.07.010 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1081872913</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576912002196</els_id><sourcerecordid>1081872913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-427da4ca8f4b1826bef859c9ec3f16513178e39388382c5a75ec9cd788eeea6e3</originalsourceid><addsrcrecordid>eNp9kc-K1TAUxosozh99A5FsBDetSds06UbQQceBAUF0HXJPTm9zSdOatIU-i0_h1oeYZzKXe9Wdi3BC-H3nOzlflr1gtGCUNW8OhfWzHaaipKwsqCgoo4-ySyaFzJmg_HG680bkXDTtRXYV44HS9F6zp9lFWcqa8YpfZj--9JuHfpz6zTnrkUwBV_RzJKCDsRqI2WK3eJjt6In2hiTLMK4YSVzCalftiPXE2WmcRrdFDdDrYA3mqTqHfo-GDBaQrFYnyZT6x2j9ngwaQrLVeyR3-cOv9w8_ydSPMZ2wOX20e5Y96bSL-Pxcr7NvHz98vfmU33--vbt5d59D1ZZzXpfC6Bq07Oodk2Wzw07yFlqEqmMNZxUTEqu2krKSJXAtOEILRkiJiLrB6jp7feqbPvZ9wTirwUZA57THcYmKUZm2WrasSmh9QtPsMQbs1BTsoMOWIHWMRR3UKRZ1jEVRoVIsSfby7LDsBjR_RX9ySMCrM6AjaNcF7cHGf1zDE9gcG709cZj2sVoMKoJFD2hsQJiVGe3_J_kNrv-0SA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1081872913</pqid></control><display><type>article</type><title>Rhynchophylline prevents cardiac dysfunction and improves survival in lipopolysaccharide-challenged mice via suppressing macrophage I-κBα phosphorylation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cao, Wenjuan ; Wang, Yuan ; Lv, Xiuxiu ; Yu, Xiaohui ; Li, Xiaojian ; Li, Hongmei ; Wang, Yanping ; Lu, Daxiang ; Qi, Renbin ; Wang, Huadong</creator><creatorcontrib>Cao, Wenjuan ; Wang, Yuan ; Lv, Xiuxiu ; Yu, Xiaohui ; Li, Xiaojian ; Li, Hongmei ; Wang, Yanping ; Lu, Daxiang ; Qi, Renbin ; Wang, Huadong</creatorcontrib><description>Myocardial dysfunction is a common complication during sepsis and significantly contributes to the mortality of patients with septic shock. However, none of the available therapeutic strategies proven to be effective in patients with severe sepsis are designed specifically to target myocardial dysfunction. The purpose of the present study is to investigate the effect of rhynchophylline (Rhy) on LPS-induced myocardial dysfunction in mice. We found that pretreatment with Rhy significantly improved cardiac systolic dysfunction, increased stroke volume and cardiac output in mice challenged with LPS. LPS induced cardiac inhibitor-κBα (I-κBα) phosphorylation, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) mRNA expression, and in turn increased cardiac TNF-α and IL-1β protein production, all of which were attenuated by pretreatment with Rhy. Immunohistochemistry revealed that TNF-α was found in infiltrated macrophages (F4/80+) and myocardium, and Rhy reduced TNF-α immunostaining in cardiac infiltrated macrophages in LPS-challenged mice. Furthermore, Rhy inhibited LPS-induced I-κBα phosphorylation and TNF-α production in cultured mouse peritoneal macrophages, but not in neonatal mouse cardiomyocytes. Pretreatment with Rhy significantly decreased the mortality of LPS-challenged mice. These results indicate that Rhy reduces cardiac dysfunction and improves survival via suppression of macrophage I-κBα phosphorylation in LPS-challenged mice, and suggest that Rhy may be a potential agent for the treatment of septic cardiac dysfunction.
[Display omitted]
► Rhynchophylline inhibited LPS-induced I-κBα phosphorylation in macrophages. ► Rhynchophylline did not block LPS-induced TNF-α production in cardiomyocytes. ► Rhynchophylline inhibited LPS-induced cardiac I-κBα phosphorylation. ► Rhynchophylline inhibited LPS-induced cardiac TNF-α and IL-1β expression. ► Rhynchophylline improved cardiac dysfunction and survival in LPS-challenged mice.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2012.07.010</identifier><identifier>PMID: 22841535</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Animals ; Animals, Newborn ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiomyopathies - drug therapy ; Cardiomyopathies - metabolism ; Cardiomyopathies - physiopathology ; Cardiotonic Agents - pharmacology ; Cardiotonic Agents - therapeutic use ; Heart ; Heart - drug effects ; Heart - physiopathology ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; I-kappa B Proteins - antagonists & inhibitors ; Indole Alkaloids - pharmacology ; Indole Alkaloids - therapeutic use ; Inhibitor-κBα ; Interleukin-1beta - genetics ; Interleukin-1beta - metabolism ; Lipopolysaccharide ; Lipopolysaccharides ; Macrophages, Peritoneal - metabolism ; Male ; Medical sciences ; Mice ; Myocardial dysfunction ; Myocardium - metabolism ; NF-KappaB Inhibitor alpha ; Pharmacology. Drug treatments ; Rhynchophylline ; RNA, Messenger - metabolism ; Tumor Necrosis Factor-alpha - genetics ; Tumor Necrosis Factor-alpha - metabolism</subject><ispartof>International immunopharmacology, 2012-11, Vol.14 (3), p.243-251</ispartof><rights>2012 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-427da4ca8f4b1826bef859c9ec3f16513178e39388382c5a75ec9cd788eeea6e3</citedby><cites>FETCH-LOGICAL-c392t-427da4ca8f4b1826bef859c9ec3f16513178e39388382c5a75ec9cd788eeea6e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2012.07.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26584160$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22841535$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cao, Wenjuan</creatorcontrib><creatorcontrib>Wang, Yuan</creatorcontrib><creatorcontrib>Lv, Xiuxiu</creatorcontrib><creatorcontrib>Yu, Xiaohui</creatorcontrib><creatorcontrib>Li, Xiaojian</creatorcontrib><creatorcontrib>Li, Hongmei</creatorcontrib><creatorcontrib>Wang, Yanping</creatorcontrib><creatorcontrib>Lu, Daxiang</creatorcontrib><creatorcontrib>Qi, Renbin</creatorcontrib><creatorcontrib>Wang, Huadong</creatorcontrib><title>Rhynchophylline prevents cardiac dysfunction and improves survival in lipopolysaccharide-challenged mice via suppressing macrophage I-κBα phosphorylation</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>Myocardial dysfunction is a common complication during sepsis and significantly contributes to the mortality of patients with septic shock. However, none of the available therapeutic strategies proven to be effective in patients with severe sepsis are designed specifically to target myocardial dysfunction. The purpose of the present study is to investigate the effect of rhynchophylline (Rhy) on LPS-induced myocardial dysfunction in mice. We found that pretreatment with Rhy significantly improved cardiac systolic dysfunction, increased stroke volume and cardiac output in mice challenged with LPS. LPS induced cardiac inhibitor-κBα (I-κBα) phosphorylation, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) mRNA expression, and in turn increased cardiac TNF-α and IL-1β protein production, all of which were attenuated by pretreatment with Rhy. Immunohistochemistry revealed that TNF-α was found in infiltrated macrophages (F4/80+) and myocardium, and Rhy reduced TNF-α immunostaining in cardiac infiltrated macrophages in LPS-challenged mice. Furthermore, Rhy inhibited LPS-induced I-κBα phosphorylation and TNF-α production in cultured mouse peritoneal macrophages, but not in neonatal mouse cardiomyocytes. Pretreatment with Rhy significantly decreased the mortality of LPS-challenged mice. These results indicate that Rhy reduces cardiac dysfunction and improves survival via suppression of macrophage I-κBα phosphorylation in LPS-challenged mice, and suggest that Rhy may be a potential agent for the treatment of septic cardiac dysfunction.
[Display omitted]
► Rhynchophylline inhibited LPS-induced I-κBα phosphorylation in macrophages. ► Rhynchophylline did not block LPS-induced TNF-α production in cardiomyocytes. ► Rhynchophylline inhibited LPS-induced cardiac I-κBα phosphorylation. ► Rhynchophylline inhibited LPS-induced cardiac TNF-α and IL-1β expression. ► Rhynchophylline improved cardiac dysfunction and survival in LPS-challenged mice.</description><subject>Animals</subject><subject>Animals, Newborn</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cardiomyopathies - drug therapy</subject><subject>Cardiomyopathies - metabolism</subject><subject>Cardiomyopathies - physiopathology</subject><subject>Cardiotonic Agents - pharmacology</subject><subject>Cardiotonic Agents - therapeutic use</subject><subject>Heart</subject><subject>Heart - drug effects</subject><subject>Heart - physiopathology</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>I-kappa B Proteins - antagonists & inhibitors</subject><subject>Indole Alkaloids - pharmacology</subject><subject>Indole Alkaloids - therapeutic use</subject><subject>Inhibitor-κBα</subject><subject>Interleukin-1beta - genetics</subject><subject>Interleukin-1beta - metabolism</subject><subject>Lipopolysaccharide</subject><subject>Lipopolysaccharides</subject><subject>Macrophages, Peritoneal - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Myocardial dysfunction</subject><subject>Myocardium - metabolism</subject><subject>NF-KappaB Inhibitor alpha</subject><subject>Pharmacology. Drug treatments</subject><subject>Rhynchophylline</subject><subject>RNA, Messenger - metabolism</subject><subject>Tumor Necrosis Factor-alpha - genetics</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc-K1TAUxosozh99A5FsBDetSds06UbQQceBAUF0HXJPTm9zSdOatIU-i0_h1oeYZzKXe9Wdi3BC-H3nOzlflr1gtGCUNW8OhfWzHaaipKwsqCgoo4-ySyaFzJmg_HG680bkXDTtRXYV44HS9F6zp9lFWcqa8YpfZj--9JuHfpz6zTnrkUwBV_RzJKCDsRqI2WK3eJjt6In2hiTLMK4YSVzCalftiPXE2WmcRrdFDdDrYA3mqTqHfo-GDBaQrFYnyZT6x2j9ngwaQrLVeyR3-cOv9w8_ydSPMZ2wOX20e5Y96bSL-Pxcr7NvHz98vfmU33--vbt5d59D1ZZzXpfC6Bq07Oodk2Wzw07yFlqEqmMNZxUTEqu2krKSJXAtOEILRkiJiLrB6jp7feqbPvZ9wTirwUZA57THcYmKUZm2WrasSmh9QtPsMQbs1BTsoMOWIHWMRR3UKRZ1jEVRoVIsSfby7LDsBjR_RX9ySMCrM6AjaNcF7cHGf1zDE9gcG709cZj2sVoMKoJFD2hsQJiVGe3_J_kNrv-0SA</recordid><startdate>20121101</startdate><enddate>20121101</enddate><creator>Cao, Wenjuan</creator><creator>Wang, Yuan</creator><creator>Lv, Xiuxiu</creator><creator>Yu, Xiaohui</creator><creator>Li, Xiaojian</creator><creator>Li, Hongmei</creator><creator>Wang, Yanping</creator><creator>Lu, Daxiang</creator><creator>Qi, Renbin</creator><creator>Wang, Huadong</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20121101</creationdate><title>Rhynchophylline prevents cardiac dysfunction and improves survival in lipopolysaccharide-challenged mice via suppressing macrophage I-κBα phosphorylation</title><author>Cao, Wenjuan ; Wang, Yuan ; Lv, Xiuxiu ; Yu, Xiaohui ; Li, Xiaojian ; Li, Hongmei ; Wang, Yanping ; Lu, Daxiang ; Qi, Renbin ; Wang, Huadong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-427da4ca8f4b1826bef859c9ec3f16513178e39388382c5a75ec9cd788eeea6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Animals, Newborn</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cardiomyopathies - drug therapy</topic><topic>Cardiomyopathies - metabolism</topic><topic>Cardiomyopathies - physiopathology</topic><topic>Cardiotonic Agents - pharmacology</topic><topic>Cardiotonic Agents - therapeutic use</topic><topic>Heart</topic><topic>Heart - drug effects</topic><topic>Heart - physiopathology</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>I-kappa B Proteins - antagonists & inhibitors</topic><topic>Indole Alkaloids - pharmacology</topic><topic>Indole Alkaloids - therapeutic use</topic><topic>Inhibitor-κBα</topic><topic>Interleukin-1beta - genetics</topic><topic>Interleukin-1beta - metabolism</topic><topic>Lipopolysaccharide</topic><topic>Lipopolysaccharides</topic><topic>Macrophages, Peritoneal - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Myocardial dysfunction</topic><topic>Myocardium - metabolism</topic><topic>NF-KappaB Inhibitor alpha</topic><topic>Pharmacology. Drug treatments</topic><topic>Rhynchophylline</topic><topic>RNA, Messenger - metabolism</topic><topic>Tumor Necrosis Factor-alpha - genetics</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cao, Wenjuan</creatorcontrib><creatorcontrib>Wang, Yuan</creatorcontrib><creatorcontrib>Lv, Xiuxiu</creatorcontrib><creatorcontrib>Yu, Xiaohui</creatorcontrib><creatorcontrib>Li, Xiaojian</creatorcontrib><creatorcontrib>Li, Hongmei</creatorcontrib><creatorcontrib>Wang, Yanping</creatorcontrib><creatorcontrib>Lu, Daxiang</creatorcontrib><creatorcontrib>Qi, Renbin</creatorcontrib><creatorcontrib>Wang, Huadong</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cao, Wenjuan</au><au>Wang, Yuan</au><au>Lv, Xiuxiu</au><au>Yu, Xiaohui</au><au>Li, Xiaojian</au><au>Li, Hongmei</au><au>Wang, Yanping</au><au>Lu, Daxiang</au><au>Qi, Renbin</au><au>Wang, Huadong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rhynchophylline prevents cardiac dysfunction and improves survival in lipopolysaccharide-challenged mice via suppressing macrophage I-κBα phosphorylation</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2012-11-01</date><risdate>2012</risdate><volume>14</volume><issue>3</issue><spage>243</spage><epage>251</epage><pages>243-251</pages><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>Myocardial dysfunction is a common complication during sepsis and significantly contributes to the mortality of patients with septic shock. However, none of the available therapeutic strategies proven to be effective in patients with severe sepsis are designed specifically to target myocardial dysfunction. The purpose of the present study is to investigate the effect of rhynchophylline (Rhy) on LPS-induced myocardial dysfunction in mice. We found that pretreatment with Rhy significantly improved cardiac systolic dysfunction, increased stroke volume and cardiac output in mice challenged with LPS. LPS induced cardiac inhibitor-κBα (I-κBα) phosphorylation, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) mRNA expression, and in turn increased cardiac TNF-α and IL-1β protein production, all of which were attenuated by pretreatment with Rhy. Immunohistochemistry revealed that TNF-α was found in infiltrated macrophages (F4/80+) and myocardium, and Rhy reduced TNF-α immunostaining in cardiac infiltrated macrophages in LPS-challenged mice. Furthermore, Rhy inhibited LPS-induced I-κBα phosphorylation and TNF-α production in cultured mouse peritoneal macrophages, but not in neonatal mouse cardiomyocytes. Pretreatment with Rhy significantly decreased the mortality of LPS-challenged mice. These results indicate that Rhy reduces cardiac dysfunction and improves survival via suppression of macrophage I-κBα phosphorylation in LPS-challenged mice, and suggest that Rhy may be a potential agent for the treatment of septic cardiac dysfunction.
[Display omitted]
► Rhynchophylline inhibited LPS-induced I-κBα phosphorylation in macrophages. ► Rhynchophylline did not block LPS-induced TNF-α production in cardiomyocytes. ► Rhynchophylline inhibited LPS-induced cardiac I-κBα phosphorylation. ► Rhynchophylline inhibited LPS-induced cardiac TNF-α and IL-1β expression. ► Rhynchophylline improved cardiac dysfunction and survival in LPS-challenged mice.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>22841535</pmid><doi>10.1016/j.intimp.2012.07.010</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1567-5769 |
ispartof | International immunopharmacology, 2012-11, Vol.14 (3), p.243-251 |
issn | 1567-5769 1878-1705 |
language | eng |
recordid | cdi_proquest_miscellaneous_1081872913 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Animals Animals, Newborn Biological and medical sciences Cardiology. Vascular system Cardiomyopathies - drug therapy Cardiomyopathies - metabolism Cardiomyopathies - physiopathology Cardiotonic Agents - pharmacology Cardiotonic Agents - therapeutic use Heart Heart - drug effects Heart - physiopathology Heart failure, cardiogenic pulmonary edema, cardiac enlargement I-kappa B Proteins - antagonists & inhibitors Indole Alkaloids - pharmacology Indole Alkaloids - therapeutic use Inhibitor-κBα Interleukin-1beta - genetics Interleukin-1beta - metabolism Lipopolysaccharide Lipopolysaccharides Macrophages, Peritoneal - metabolism Male Medical sciences Mice Myocardial dysfunction Myocardium - metabolism NF-KappaB Inhibitor alpha Pharmacology. Drug treatments Rhynchophylline RNA, Messenger - metabolism Tumor Necrosis Factor-alpha - genetics Tumor Necrosis Factor-alpha - metabolism |
title | Rhynchophylline prevents cardiac dysfunction and improves survival in lipopolysaccharide-challenged mice via suppressing macrophage I-κBα phosphorylation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T16%3A42%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rhynchophylline%20prevents%20cardiac%20dysfunction%20and%20improves%20survival%20in%20lipopolysaccharide-challenged%20mice%20via%20suppressing%20macrophage%20I-%CE%BAB%CE%B1%20phosphorylation&rft.jtitle=International%20immunopharmacology&rft.au=Cao,%20Wenjuan&rft.date=2012-11-01&rft.volume=14&rft.issue=3&rft.spage=243&rft.epage=251&rft.pages=243-251&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2012.07.010&rft_dat=%3Cproquest_cross%3E1081872913%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1081872913&rft_id=info:pmid/22841535&rft_els_id=S1567576912002196&rfr_iscdi=true |